10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2011 | |||
CONSOLIDATED STATEMENTS OF EARNINGS | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 17, 2012) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Net Sales | $ 21,244 | 19,484 | 18,808 |
| Cost of products sold | 5,598 | 5,277 | 5,140 |
| Marketing, selling and administrative | 4,203 | 3,686 | 3,946 |
| Advertising and product promotion | 957 | 977 | 1,136 |
| Research and development | 3,839 | 3,566 | 3,647 |
| Provision for restructuring | 116 | 113 | 136 |
| Litigation expense, net | (19) | 132 | |
| Equity in net income of affiliates | (281) | (313) | (550) |
| Other (income)/expense | (169) | 126 | (381) |
| Total Expenses | 14,263 | 13,413 | 13,206 |
| Earnings from Continuing Operations Before Income Taxes | 6,981 | 6,071 | 5,602 |
| Provision for income taxes | 1,721 | 1,558 | 1,182 |
| Net Earnings from Continuing Operations | 5,260 | 4,513 | 4,420 |
| Discontinued Operations: | |||
| Earnings, net of taxes | 285 | ||
| Gain on disposal, net of taxes | 7,157 | ||
| Net Earnings from Discontinued Operations | 7,442 | ||
| Net Earnings | 5,260 | 4,513 | 11,862 |
| Net Earnings Attributable to Noncontrolling Interest | 1,551 | 1,411 | 1,250 |
| Net Earnings Attributable to Bristol-Myers Squibb Company | 3,709 | 3,102 | 10,612 |
| Amounts Attributable to Bristol-Myers Squibb Company | |||
| Net earnings from continuing operations attributable to Bristol-Myers Squibb Company | 3,709 | 3,102 | 3,239 |
| Net earnings from discontinued operations attributable to Bristol-Myers Squibb Company | 7,373 | ||
| Earnings per Common Share | |||
| Basic Earnings per Common Share from Continuing Operations Attributable to Bristol-Myers Squibb Company | 2.1800 | 1.8000 | 1.6300 |
| Diluted Earnings per Common Share from Continuing Operations Attributable to Bristol-Myers Squibb Company | 2.1600 | 1.7900 | 1.6300 |
| Basic Earnings Per Common Share Attributable to Bristol-Myers Squibb Company | 2.1800 | 1.8000 | 5.3500 |
| Diluted Earnings per Common Share Attributable to Bristol-Myers Squibb Company | 2.1600 | 1.7900 | 5.3400 |
| Dividends declared per common share | 1.3300 | 1.2900 | 1.2500 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2011 | |||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 17, 2012) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| COMPREHENSIVE INCOME | |||
| Net Earnings | $ 5,260 | 4,513 | 11,862 |
| Other Comprehensive Income/(Loss): | |||
| Foreign currency translation | (27) | 37 | 159 |
| Foreign currency translation reclassified to net earnings due to business divestitures | (40) | ||
| Foreign currency translation on net investment hedges | 11 | 84 | (38) |
| Derivatives qualifying as cash flow hedges, net of taxes of $(4) in 2011, $(3) in 2010 and $9 in 2009 | 24 | 15 | (19) |
| Derivatives qualifying as cash flow hedges reclassified to net earnings, net of taxes of $(20) in 2011, $5 in 2010 and $5 in 2009 | 32 | (5) | (27) |
| Derivatives reclassified to net earnings due to business divestitures, net of taxes of $(1) in 2009 | 2 | ||
| Pension and postretirement benefits, net of taxes of $421 in 2011, $66 in 2010 and $41 in 2009 | (830) | (88) | (115) |
| Pension and postretirement benefits reclassified to net earnings, net of taxes of $(38) in 2011, $(44) in 2010 and $(49) in 2009 | 88 | 83 | 109 |
| Pension and postretirement benefits reclassified to net earnings due to business divestitures, net of taxes of $(62) in 2009 | 106 | ||
| Available for sale securities, net of taxes of $(7) in 2011, $(3) in 2010 and $(4) in 2009 | 28 | 44 | 35 |
| Available for sale securities reclassified to net earnings, net of taxes of $(3) in 2009 | 6 | ||
| Total Other Comprehensive Income/(Loss) | (674) | 170 | 178 |
| Comprehensive Income | 4,586 | 4,683 | 12,040 |
| Comprehensive Income Attributable to Noncontrolling Interest | 1,558 | 1,411 | 1,260 |
| Comprehensive Income Attributable to Bristol-Myers Squibb Company | 3,028 | 3,272 | 10,780 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2011 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 17, 2012) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Cash Flows From Operating Activities: | |||
| Net Earnings | $ 5,260 | 4,513 | 11,862 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | |||
| Net earnings attributable to noncontrolling interest | (1,551) | (1,411) | (1,250) |
| Depreciation | 448 | 473 | 469 |
| Amortization | 353 | 271 | 238 |
| Deferred income tax expense | 415 | 422 | |
| Deferred income tax expense | 163 | ||
| Stock-based compensation expense | 161 | 193 | 183 |
| Impairment charges | 28 | 228 | |
| Gain related to divestitures of discontinued operations | (7,275) | ||
| Other adjustments | (147) | (32) | (367) |
| Changes in operating assets and liabilities: | |||
| Receivables | (220) | (270) | 227 |
| Inventories | (193) | 156 | 82 |
| Accounts payable | 593 | 315 | 472 |
| Deferred income | (115) | 117 | 135 |
| U.S. and foreign income taxes payable | (134) | (236) | 58 |
| Other | (58) | (248) | (932) |
| Net Cash Provided by Operating Activities | 4,840 | 4,491 | 4,065 |
| Cash Flows From Investing Activities: | |||
| Proceeds from sale and maturities of marketable securities | 5,960 | 3,197 | 2,075 |
| Purchases of marketable securities | (6,819) | (5,823) | (3,489) |
| Additions to property, plant and equipment and capitalized software | (367) | (424) | (730) |
| Proceeds from sale of businesses and other investing activities | 67 | 557 | |
| Proceeds from sale of businesses and other investing activities | 149 | ||
| Mead Johnson's cash at split-off | (561) | ||
| Purchases of businesses, net of cash acquired | (360) | (829) | (2,232) |
| Net Cash Used in Investing Activities | (1,437) | (3,812) | (4,380) |
| Cash Flows From Financing Activities: | |||
| Short-term debt repayments | (1) | (33) | (26) |
| Long-term debt borrowings | 6 | 1,683 | |
| Long-term debt repayments | (78) | (936) | (212) |
| Interest rate swap terminations | 296 | 146 | 194 |
| Issuances of common stock | 601 | 252 | 45 |
| Common stock repurchases | (1,221) | (576) | |
| Dividends paid | (2,254) | (2,202) | (2,483) |
| Proceeds from Mead Johnson initial public offering | 782 | ||
| Net Cash Used in Financing Activities | (2,657) | (3,343) | (17) |
| Effect of Exchange Rates on Cash and Cash Equivalents | (3) | 14 | 39 |
| (Decrease)/Increase in Cash and Cash Equivalents | 743 | (2,650) | (293) |
| Cash and Cash Equivalents at Beginning of Period | 5,033 | 7,683 | |
| Cash and Cash Equivalents at End of Period | 5,776 | 5,033 | 7,683 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2011 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2011 10-K (Filed: Feb 17, 2012) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2011 | Dec 31, 2010 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 5,776 | 5,033 |
| Marketable securities | 2,957 | 2,268 |
| Receivables | 3,743 | 3,480 |
| Inventories | 1,384 | 1,204 |
| Deferred income taxes | 1,200 | 1,036 |
| Prepaid expenses and other | 258 | 252 |
| Total Current Assets | 15,318 | 13,273 |
| Property, plant and equipment | 4,521 | 4,664 |
| Goodwill | 5,586 | 5,233 |
| Other intangible assets | 3,124 | 3,370 |
| Deferred income taxes | 688 | 850 |
| Marketable securities | 2,909 | 2,681 |
| Other assets | 824 | 1,005 |
| Total Assets | 32,970 | 31,076 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term borrowings | 115 | 117 |
| Accounts payable | 2,603 | 1,983 |
| Accrued expenses | 2,791 | 2,740 |
| Deferred income | 337 | 402 |
| Accrued rebates and returns | 1,170 | 857 |
| U.S. and foreign income taxes payable | 167 | 65 |
| Dividends payable | 597 | 575 |
| Total Current Liabilities | 7,780 | 6,739 |
| Pension, postretirement, and postemployment liabilities | 2,017 | 1,297 |
| Deferred income | 866 | 895 |
| U.S. and foreign income taxes payable | 573 | 755 |
| Other liabilities | 491 | 424 |
| Long-term debt | 5,376 | 5,328 |
| Total Liabilities | 17,103 | 15,438 |
| Commitments and contingencies (Note 22) | 0 | 0 |
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders' Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,268 in 2011 and 5,269 in 2010, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2011 and 2010 | 220 | 220 |
| Capital in excess of par value of stock | 3,114 | 3,682 |
| Accumulated other comprehensive loss | (3,045) | (2,371) |
| Retained earnings | 33,069 | 31,636 |
| Less cost of treasury stock - 515 million common shares in 2011 and 501 million in 2010 | (17,402) | (17,454) |
| Total Bristol-Myers Squibb Company Shareholders' Equity | 15,956 | 15,713 |
| Noncontrolling interest | (89) | (75) |
| Total Equity | 15,867 | 15,638 |
| Total Liabilities and Equity | 32,970 | 31,076 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2011 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |